NEW YORK– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corporate Affairs Officer. Ms. Fagan will serve as a member of the executive team and will oversee public affairs and corporate communications for the Company.
“I want to welcome Stephanie to the MindMed team. Stephanie’s track record leading and executing successful multi-stakeholder strategies will be critical as we advance MM120 into pivotal trials and ultimately to the market. This new role underscores our commitment to deepening engagement with our partners and communities as we continue to build MindMed into a leading biopharmaceutical company developing novel products to treat brain health disorders,” said Rob Barrow, Chief Executive Officer of MindMed.
“MindMed is pioneering the future of brain health with potential groundbreaking treatments, and I am thrilled to join a company dedicated to transforming patient outcomes in an area of immense public health need,” said Stephanie Fagan, MindMed’s newly appointed Chief Corporate Affairs Officer. “I look forward to collaborating with our team and engaging deeply with the communities we serve to realize the full therapeutic potential of MM120 for generalized anxiety disorder and to advance our innovative pipeline of product candidates.”
Stephanie Fagan brings over 20 years of experience as an executive in the healthcare industry leading strategies that drive organizational success through innovative communication and stakeholder engagement. Ms. Fagan joins MindMed from Agenus where she was Chief Communications Officer and before that, she was Senior Vice President, Corporate Affairs and Chief Communications Officer at Acadia Pharmaceuticals, overseeing all internal and external communications. She joined Acadia from bluebird bio, Inc., where she was Senior Vice President, Corporate Communications, and built the first communications function as the company transitioned from a clinical to a commercial-stage company. Prior to bluebird, she led corporate affairs and communications functions at Alexion, Shire and West Health. Over the course of her career, Ms. Fagan has served in positions of increasing influence and impact in the healthcare industry, including roles at Johnson & Johnson, Allergan, Pharmacia, Inc. (now Pfizer), and Boston Scientific Corporation.
Ms. Fagan earned a Master of Science in Mass Communications from Boston University and a Bachelor of Arts in English from Wheaton College.
